Association between Hepatocellular Carcinoma Recurrence and Graft Size in Living Donor Liver Transplantation: A Systematic Review

Int J Mol Sci. 2023 Mar 25;24(7):6224. doi: 10.3390/ijms24076224.

Abstract

The aim of this work was to assess the association between graft-to-recipient weight ratio (GRWR) in adult-to-adult living donor liver transplantation (LDLT) and hepatocellular carcinoma (HCC) recurrence. A search of the MEDLINE and EMBASE databases was performed until December 2022 for studies comparing different GRWRs in the prognosis of HCC recipients in LDLT. Data were pooled to evaluate 1- and 3-year survival rates. We identified three studies, including a total of 782 patients (168 GRWR < 0.8 vs. 614 GRWR ≥ 0.8%). The pooled overall survival was 85% and 77% at one year and 90% and 83% at three years for GRWR < 0.8 and GRWR ≥ 0.8, respectively. The largest series found that, in patients within Milan criteria, the GRWR was not associated with lower oncological outcomes. However, patients with HCC outside the Milan criteria with a GRWR < 0.8% had lower survival and higher tumor recurrence rates. The GRWR < 0.8% appears to be associated with lower survival rates in HCC recipients, particularly for candidates with tumors outside established HCC criteria. Although the data are scarce, the results of this study suggest that considering the individual GRWR not only as risk factor for small-for-size-syndrome but also as contributor to HCC recurrence in patients undergoing LDLT would be beneficial. Novel perfusion technologies and pharmacological interventions may contribute to improving outcomes.

Keywords: graft size; graft-to-recipient weight ratio; hepatocellular carcinoma; living donor liver transplantation; tumor recurrence.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Adult
  • Carcinoma, Hepatocellular* / etiology
  • Carcinoma, Hepatocellular* / surgery
  • Humans
  • Liver
  • Liver Neoplasms* / etiology
  • Liver Neoplasms* / surgery
  • Liver Transplantation* / methods
  • Living Donors
  • Retrospective Studies
  • Risk Factors
  • Treatment Outcome

Grants and funding

This research received no external funding.